| 02:14a | Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products -- Update | DJ |
| 02:02a | Roche flags 2023 earnings decline on slump in COVID products | RE |
| 01:47a | Roche 2022 Sales Grew, But Expects 2023 Decline on Covid-19 Products | DJ |
| 01:29a | Roche's FY22 Profit Falls as COVID-19 Boost Fades | MT |
| 12:47a | Formycon Licenses Stelara Biosimilar Candidate to Fresenius Unit | MT |
| 02/01 | Merck & Co. Says No Direct Evidence of COVID-19 Pill Leading to New Variants | MT |
| 02/01 | Global markets live: AMD, Amgen, Electronic Arts, PayPal, Snap... | |
| 02/01 | Trending: Novartis's 4Q Net Profit Declines on Poor Drug Performances | DJ |
| 02/01 | Novo Nordisk Q4 Earnings, Sales Rise; Issues 2023 Outlook; to Start 28 Billion Kroner S.. | MT |
| 02/01 | NOVO NORDISK : Jefferies gives a Sell rating | MD |
| 02/01 | Transcript : Novo Nordisk A/S, 2022 Earnings Call, Feb 01, 2023 | CI |
| 02/01 | NOVO NORDISK : Sell rating from UBS | MD |
| 02/01 | NOVO NORDISK : JP Morgan maintains a Buy rating | MD |
| 02/01 | Scancell Holdings Names Jean-Michel Cossery Nonexecutive Chairman | DJ |
| 02/01 | European shares gain on pharma boost; Fed policy decision on tap | RE |
| 02/01 | Novo Nordisk Launches $4 Billion Buyback as 4Q Earnings Beat Forecasts | DJ |
| 02/01 | Novo Nordisk to Launch New DKK28 Billion Share Repurchase Program | MT |
| 02/01 | Novo Nordisk Reports 16% Jump in FY22 Net Profit on Double-Digit Sales Growth | MT |
| 02/01 | Novartis Lifts Dividend Despite 4Q Sales, Profit Decline | DJ |
| 02/01 | European Commission Expands Marketing Permit for Roche's Hemlibra | MT |
| 01/31 | Amgen revenue falls slightly as Lilly COVID deal contributes less | RE |
| 01/31 | Moody's Says Johnson & Johnson's Court Loss is Negative Credit Development | MT |
| 01/31 | Global markets live: GM, Pfizer, Exxon, UBS, Boeing... | |
| 01/31 | UBS Adjusts Eli Lilly and Company Price Target to $406 From $420, Maintains Buy Rating | MT |
| 01/31 | UBS Adjusts Merck & Company Price Target to $108 From $105, Maintains Neutral Rating | MT |
| 01/31 | Idorsia Files European Marketing Authorization Application For Resistant Hypertension T.. | MT |
| 01/31 | PrescriberPoint, Inc. announced that it has received funding from Eli Lilly and Company.. | CI |
| 01/31 | Carsgen Therapeutics Holdings Limited Announces Collaboration Agreement with F. Hoffman.. | CI |
| 01/30 | Roche's Diagnostics Division Joins Jana Care on Remote Blood Testing Platform | MT |
| 01/30 | Sector Update: Health Care Stocks' Losses Gain Speed Near Monday Close | MT |
| 01/30 | Sector Update: Health Care | MT |
| 01/30 | Johnson & Johnson Worst Performer in the DJIA So Far Today -- Data Talk | DJ |
| 01/30 | Top Midday Decliners | MT |
| 01/30 | Jana Care, Inc. to Enter Collaboration with Roche Diagnostics to Develop and Distribute.. | CI |
| 01/30 | Mega-Cap Tech Earnings on Tap; Fed's Policy Leanings Cool US Equity Investors' Risk App.. | MT |
| 01/30 | Drugmakers prevail in dispute over U.S. discount drug program | RE |
| 01/30 | AstraZeneca Doses First Patient in Phase 3 Study of Datopotamab Deruxtecan to Treat Lun.. | MT |
| 01/30 | Johnson & Johnson's Bankruptcy Petition for Talc Unit Dismissed by Court; Shares Down M.. | MT |
| 01/30 | Johnson & Johnson Stock Falls Amid Reports US Appeals Court Rejected Company's Use of B.. | MT |
| 01/30 | Johnson & Johnson Talc Bankruptcy Case Thrown Out b.. | MT |
| 01/30 | Daiichi begins Tropion-Lung07 phase 3 trial for lung cancer treatment | AN |
| 01/30 | European Equities Start the Week Modestly Higher Amid German GDP Contraction | MT |
| 01/30 | Berenberg Bank Adjusts Merck & Company Price Target to $125 From $115, Maintains Buy Ra.. | MT |
| 01/30 | Berenberg Lowers Price Target on Roche, Maintains Buy Recommendation | MT |
| 01/30 | ROCHE HOLDINGS AG : Berenberg reiterates its Buy rating | MD |
| 01/27 | Eli Lilly's Oncology Unit Gets US FDA's Approval for Mantle Cell Lymphoma Drug | MT |
| 01/27 | FDA Approves Eli Lilly's Jaypirca to Treat Lymphoma Patients | DJ |
| 01/27 | Eli Lilly Receives US FDA's Nod of Jaypirca to Treat Mantle Cell Lymphoma | MT |
| 01/27 | Eli Lilly and Company Announces That the U.S. Food and Drug Administration Approved Jay.. | CI |
| 01/27 | Johnson & Johnson's Janssen Says Carvykti Meets Target in Late-Stage Blood Cancer Trial | MT |
| 01/27 | Eli Lilly's Diabetes Drug Recommended for Approval by European Medicines Agency Committ.. | MT |
| 01/27 | Johnson & Johnson Unit Withdraws European Application for Imbruvica Drug Combination to.. | MT |
| 01/27 | Merck Says Keytruda Approved by FDA as Adjuvant Treatment for Non-Small Cell Lung Cance.. | MT |
| 01/27 | Merck Announces the U.S. Food and Drug Administration has Approved KEYTRUDA | CI |
| 01/26 | Merck & Co.'s Animal Health Unit Wins US FDA Nod for Expanded Use of Flea Drug for Dogs | MT |
| 01/26 | Sector Update: Healthcare Stocks Climb Back to Finish Higher | MT |
| 01/26 | Merck Animal Health Division Says US FDA Approves Expanded Indication of Bravecto Chews.. | MT |
| 01/26 | Eli Lilly Earmarks $1 Million to Boost Cold Chain Capacity in 17 Countries | MT |
| 01/26 | Sector Update: Health Care Stocks Advance Pre-Bell Thursday | MT |
| 01/26 | Evotec, Johnson & Johnson's Janssen Biotech Enter Cancer Drug Development Collaboration | MT |
| 01/26 | Evotec Shares Climb After Agreement With Janssen on Immunotherapies Development | DJ |
| 01/26 | Evotec Starts Oncology-development Collaboration With Johnson & Johnson Unit | MT |
| 01/26 | Roche Develops New COVID-19 PCR Test for Omicron Subvariant XBB.1.5 | MT |
| 01/26 | Roche launches new test to detect fast spreading Omicron sub-variant | RE |
| 01/26 | Roche Launches COVID-19 PCR Test to Detect the Fast Spreading XBB.1.5 Omicron Sub-Varia.. | CI |
| 01/25 | Merck & Co.'s Keytruda Combo Prolongs Survival in Late-stage Biliary Tract Cancer Study | MT |
| 01/25 | Morgan Stanley Adjusts Price Target on Johnson & Johnson to $180 From $176, Maintains E.. | MT |
| 01/25 | Roche, Sysnav to Develop Outcome Measurements for Movement Impairment Ailments | MT |
| 01/25 | NOVO NORDISK : Buy rating from JP Morgan | MD |
| 01/25 | Atlantic Equities Adjusts Johnson & Johnson's Price Target to $168 From $160, Keeps Neu.. | MT |
| 01/25 | Novo Nordisk Signs New License Agreement with Howwe Technologies | MT |
| 01/25 | Merck to Cease Phase 3 Trial for Treatment of Prostate Cancer Due to Failure in Meeting.. | MT |
| 01/25 | Merck Reports Keytruda Phase 3 Success, Failure | DJ |
| 01/25 | Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamid.. | CI |
| 01/25 | Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall.. | CI |
| 01/25 | NOVO NORDISK : Receives a Buy rating from Goldman Sachs | MD |
| 01/25 | ROCHE HOLDINGS AG : Barclays reaffirms its Buy rating | MD |
| 01/25 | NOVO NORDISK : Barclays keeps its Buy rating | MD |
| 01/25 | Sysnav Healthcare Announces A Multi-Year Collaboration with Roche Based on Sysnav's Pro.. | CI |
| 01/25 | RLS Global Chairman to Depart in February; Successor Nominated | MT |
| 01/24 | Sector Update: Health Care Stocks Still Sagging Near Close | MT |
| 01/24 | Merck & Company Keeps Quarterly Dividend at $0.73 a Share; Payable April 10 to Holders .. | MT |
| 01/24 | Surprise Manufacturing Gain Leaves Equities Mixed | MT |
| 01/24 | Sector Update: Health Care Stocks Retreating on Tuesday | MT |
| 01/24 | Sector Update: Health Care | MT |
| 01/24 | Merck Announces Dividend for the Second-Quarter of 2023 , Payable on April 10, 2023 | CI |
| 01/24 | Technology Heavyweights Earnings Kick-Start, Unexpected Improvement in Manufacturing In.. | MT |
| 01/24 | Johnson & Johnson on Track for Longest Losing Streak Since August 1981 -- Data Talk | DJ |
| 01/24 | Johnson &Johnson CFO on Earnings Forecast, Costs, and Consumer Spinoff | MT |
| 01/24 | Global markets live: GE, J&J, Verizon, Lockheed Martin, Halliburton... | |
| 01/24 | Sector Update: Health Care Stocks Flat to Lower Pre-Bell Tuesday | MT |
| 01/24 | Prospect of Further Federal Reserve Interest Rate Increases Pressuring Exchange-Traded .. | MT |
| 01/24 | Johnson & Johnson Fourth-Quarter Revenue Falls on Lower COVID-19 Vaccine Sales; Guides .. | MT |
| 01/24 | Transcript : Johnson & Johnson, Q4 2022 Earnings Call, Jan 24, 2023 | CI |
| 01/24 | FTSE 100 down as UK PMIs raise recession fears | AN |
| 01/24 | Eli Lilly to Allocate Another $450 Million Toward Manufacturing Capacity Expansion at N.. | MT |
| 01/24 | Johnson & Johnson Q4 Adjusted Profit Rises; Sales Drop; Full-Year 2023 Guidance Release.. | MT |
| 01/24 | Eli Lilly Plans $450 Million Investment To Expand US Manufacturing Site | MT |
| 01/24 | Eli Lilly and Company Plans to Invest Additional $450 Million At Manufacturing Site in .. | CI |
| 01/24 | Earnings Flash (JNJ) JOHNSON & JOHNSON Reports Q4 Revenue $23.71B, vs. Street Est of $2.. | MT |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
